Published in AIDS Weekly, February 3rd, 1997
The DSMB is continuing in session to review additional data over the coming weeks. No safety problems were reported in the interim review. HIV-IG is NABI's immunotherapeutic product in development for the prevention of HIV transmission from mother to infant and is currently in a Phase III randomized, double-blind, controlled study.
To date, 459 mothers have been enrolled in the study, and 432 babies have been born to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.